All In Biotech

Free tool

FAERS Monitor: Altafluor Benox

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208582 or its brand name (Altafluor Benox, Benoxinate Hydrochloride, Fluorescein Sodium). Reports on generic versions are filed under their own applications.

Reports

9

Serious

7

78% of reports

Hospitalization

0

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • confusional state2
  • eye pain2
  • headache2
  • nausea2
  • rash2
  • syncope2
  • abdominal pain upper1
  • abnormal sensation in eye1
  • blood glucose decreased1
  • device calibration failure1
  • disorientation1
  • dizziness1
  • documented hypersensitivity to administered product1
  • dry eye1
  • dysarthria1

Reports by year received

View as table
YearReports
20151
20191
20211
20232
20243
20261

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,150 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
device calibration failure144987.56949.011,034
documented hypersensitivity to administered product12849.4448.4711
abnormal sensation in eye1543.885.7135
eye pain282.824.490
dysarthria162.19.815
disorientation159.09.314
blood glucose decreased148.77.711
dry eye146.87.411
syncope246.713.850
confusional state228.98.530
abdominal pain upper111.41.82
rash210.73.29
headache27.52.26
nausea25.91.74
dizziness14.70.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.